|drug3531||Treatment and prophylaxis Wiki||1.00|
|drug3205||Standard Public Health measures Wiki||1.00|
|drug1502||Hospital admission Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
This is a registry-based cohort study of all adult patients (≥18 years) with confirmed or suspected SARS-CoV-2 infection. The main goal is to describe mortality incidence, demographic characteristics, coexisting conditions, treatments, outcomes among SARS-CoV2 infected patients. A secondary goal is to identify biological factors (OMICS - genomic, proteomic and metabolomics characterization) associated with severity conditions for these patients.
Description: All-cause mortality rates at 60 daysMeasure: All-cause mortality Time: 60 Days
Description: To assess the prevalence and course of symptoms of COVID-19 infection of patients followed during a period of 60 daysMeasure: Incidence and course of symptoms of COVID-19 infection Time: 60 Days
Description: Rate of patients requiring hospitalization and re-hospitalization (readmission to the hospital occurring within 60 days after admission)Measure: Hospitalizations Time: 60 Days
Description: Rate of patients requiring oxygen therapyMeasure: Oxygen supplementation Time: 60 Days
Description: Rate of patients requiring invasive mechanical ventilationMeasure: Use of invasive mechanical ventilation Time: 60 Days
Description: ICU length of stayMeasure: Intensive care unit length of stay Time: 60 Days
Description: Percentual changes in serum proteome of patients with mild or moderate to severe diseaseMeasure: Serum proteomic Time: 60 Days
Description: Percentual changes in serum metabolome of patients with mild or moderate to severe diseaseMeasure: Serum metabolomic Time: 60 Days
Description: Determination of whole genome sequence and transcriptomic of mild or moderate to severe diseaseMeasure: Genomic description Time: 60 Days
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports